What Will it Take to Eliminate Pediatric HIV? Reaching WHO Target Rates of Mother-to-Child HIV Transmission in Zimbabwe: A Model-Based Analysis by Perez, Freddy et al.
 
What Will it Take to Eliminate Pediatric HIV? Reaching WHO
Target Rates of Mother-to-Child HIV Transmission in Zimbabwe: A
Model-Based Analysis
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Ciaranello, Andrea L., Freddy Perez, Jo Keatinge, Ji-Eun Park,
Barbara Engelsmann, Matthews Maruva, Rochelle P. Walensky, et
al. 2012. What will it take to eliminate pediatric HIV? Reaching
WHO target rates of mother-to-child HIV transmission in
zimbabwe: A model-based analysis. PLoS Medicine 9(1):
e1001156.
Published Version doi:10.1371/journal.pmed.1001156
Accessed February 19, 2015 9:49:17 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:9368044
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAWhat Will It Take to Eliminate Pediatric HIV? Reaching
WHO Target Rates of Mother-to-Child HIV Transmission
in Zimbabwe: A Model-Based Analysis
Andrea L. Ciaranello
1*, Freddy Perez
2,3, Jo Keatinge
4, Ji-Eun Park
5, Barbara Engelsmann
6, Matthews
Maruva
4, Rochelle P. Walensky
1,7,10, Francois Dabis
2, Jennifer Chu
5, Asinath Rusibamayila
5, Angela
Mushavi
8, Kenneth A. Freedberg
1,5,9,10
1Division of Infectious Disease, Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America, 2INSERM U897
Africa Team of the Institut de Sante ´ Publique, d’Epide ´miologie et de De ´veloppement, Universite ´ Bordeaux Segalen, Bordeaux, France, 3HIV/AIDS Unit, Pan American
Health Organization, Washington, District of Columbia, United States of America, 4Zimbabwe Country Office, Elizabeth Glaser Pediatric AIDS Foundation, Harare,
Zimbabwe, 5Division of General Medicine, Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, United States of America,
6Organization of Public Health Interventions and Development, Harare, Zimbabwe, 7Division of Infectious Disease, Brigham and Women’s Hospital, Boston,
Massachusetts, United States of America, 8Ministry of Health and Child Welfare, Harare, Zimbabwe, 9Department of Health Policy and Management, Harvard School of
Public Health, Boston, Massachusetts, United States of America, 10Harvard University Center for AIDS Research, Boston, Massachusetts, United States of America
Abstract
Background: The World Health Organization (WHO) has called for the ‘‘virtual elimination’’ of pediatric HIV: a mother-to-
child HIV transmission (MTCT) risk of less than 5%. We investigated uptake of prevention of MTCT (PMTCT) services, infant
feeding recommendations, and specific drug regimens necessary to achieve this goal in Zimbabwe.
Methods and Findings: We used a computer model to simulate a cohort of HIV-infected, pregnant/breastfeeding women
(mean age, 24 y; mean CD4, 451/ml; breastfeeding duration, 12 mo). Three PMTCT regimens were evaluated: (1) single-dose
nevirapine (sdNVP), (2) WHO 2010 guidelines’ ‘‘Option A’’ (zidovudine in pregnancy, infant nevirapine throughout
breastfeeding for women without advanced disease, lifelong combination antiretroviral therapy for women with advanced
disease), and (3) WHO ‘‘Option B’’ (pregnancy/breastfeeding-limited combination antiretroviral drug regimens without
advanced disease; lifelong antiretroviral therapy with advanced disease). We examined four levels of PMTCT uptake
(proportion of pregnant women accessing and adhering to PMTCT services): reported rates in 2008 and 2009 (36% and 56%,
respectively) and target goals in 2008 and 2009 (80% and 95%, respectively). The primary model outcome was MTCT risk at
weaning. The 2008 sdNVP-based National PMTCT Program led to a projected 12-mo MTCT risk of 20.3%. Improved uptake in
2009 reduced projected risk to 18.0%. If sdNVP were replaced by more effective regimens, with 2009 (56%) uptake,
estimated MTCT risk would be 14.4% (Option A) or 13.4% (Option B). Even with 95% uptake of Option A or B, projected
transmission risks (6.1%–7.7%) would exceed the WHO goal of less than 5%. Only if the lowest published transmission risks
were used for each drug regimen, or breastfeeding duration were shortened, would MTCT risks at 95% uptake fall below
5%.
Conclusions: Implementation of the WHO PMTCT guidelines must be accompanied by efforts to improve access to PMTCT
services, retain women in care, and support medication adherence throughout pregnancy and breastfeeding, to approach
the ‘‘virtual elimination’’ of pediatric HIV in Zimbabwe.
Please see later in the article for the Editors’ Summary.
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When antiretroviral drugs (ARVs) are administered during
pregnancy, and breastfeeding is avoided, mother-to-child HIV
transmission (MTCT) may occur in fewer than 1% of pregnancies
[1]. These highly effective prevention strategies have led the
pediatric HIV epidemic to be nearly eliminated in the United
States and Europe [1,2]. In settings where breastfeeding is
recommended for improved infant health [3], recent trials have
demonstrated that the provision of ARVs to breastfeeding mothers
or their infants can reduce total MTCT rates to 1%–5% at 6 mo
of age [4–15]. Based on these encouraging results, in 2009, HIV
prevention and treatment organizations emphasized a new goal:
the ‘‘virtual elimination’’ of pediatric HIV infection, defined as the
reduction of MTCT to less than 5% [16–20]. Toward this goal,
the World Health Organization (WHO) released new guidelines
for the prevention of MTCT (PMTCT) in 2010, based on
combination antiretroviral therapy (ART) for women with
advanced HIV disease, and country-level selection between two
antiretroviral options during pregnancy and breastfeeding (‘‘Op-
tion A’’ or ‘‘Option B’’) for women with less advanced disease
[21]. Option A includes zidovudine (ZDV) during pregnancy and
single-dose nevirapine (sdNVP) at delivery, followed by daily
nevirapine (NVP) syrup for infants throughout the duration of
breastfeeding; Option B includes maternal triple-drug ARV
regimens throughout pregnancy and breastfeeding (Table A in
Text S1) [21].
However, opportunities for PMTCT may be lost at each step in
a ‘‘cascade’’ of care, from presentation to antenatal care (ANC),
through HIV testing and result receipt, to ARV adherence
through the many months of pregnancy and breastfeeding
(Figure 1; Figure A in Text S1 [22–25]. The WHO estimates
that only 53% of pregnant women worldwide received any ARVs
for PMTCT in 2009 [19]. As a result, more than 370,000 new
perinatal HIV infections were estimated to have occurred in 2009;
the majority of these were in sub-Saharan Africa, where access to
pediatric HIV therapy is limited and infant mortality is extremely
high [19,26].
Since 2002, the Zimbabwean national PMTCT program has
provided ART to pregnant women with clinical evidence of WHO
stage 3/4 disease, and sdNVP to all others [27]. As in many sub-
Saharan African countries where prolonged breastfeeding is
common, Zimbabwe is implementing the 2010 WHO guidelines
with Option A. Because of the challenges of enrolling and
retaining women in care at each step in the PMTCT cascade, it is
not known how effective this strategy will be. We used a simulation
model to project the level of PMTCT uptake in Zimbabwe, the
PMTCT drug regimens, and the duration of breastfeeding that
would be necessary to reach the WHO ‘‘virtual elimination’’ goal
of an MTCT risk below 5%.
Methods
Analytic Overview
We expanded a validated computer simulation model of MTCT
[28,29] to include each step in the ‘‘cascade’’ of PMTCT-related
care, from first presentation at ANC through 2 y postpartum
(Figure A in Text S1). The MTCT model simulates a single
pregnancy, delivery, and postpartum period for each mother–
infant pair, and projects infant outcomes at birth. Additional
clinical events for mothers and infants through 2 y after delivery
are simulated using the CEPAC (Cost-Effectiveness of Preventing
Figure 1. Two dimensions for potential improvements in PMTCT in Zimbabwe. This figure shows the ‘‘two dimensions’’ in which PMTCT
services can be improved. First, along the vertical arrow, PMTCT programs can transition to more intensive drug regimens (i.e., from sdNVP to Option
A to Option B). Second, along the horizontal arrow, programs can undertake interventions to improve ‘‘uptake’’ of PMTCT services, defined as the
proportion of pregnant, HIV-infected women who receive and adhere to ARVs for PMTCT, for example, from 36% in 2008 to 56% in 2009, and perhaps
to 80% or 95% with future scale-up effort. Within the horizontal arrow are depicted the three ‘‘domains’’ of uptake examined in these analyses: care
and testing, drug availability, or retention. sdNVP represents the current National PMTCT Program, based largely on sdNVP; ‘‘Option A’’ and ‘‘Option
B’’ are the WHO 2010 PMTCT guideline-recommended regimens, as defined in the text and Text S1.
doi:10.1371/journal.pmed.1001156.g001
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primary outcome of the linked CEPAC and MTCT models is risk
of infant HIV transmission at the time of weaning; secondary
outcomes include HIV infection risk at 4–6 wk of age, 2-y
pediatric survival, and 2-y HIV-free pediatric survival.
This analysis examined improvements along two dimensions of
PMTCT care: more effective PMTCT regimens, and improved
uptake of the PMTCT ‘‘cascade’’ (Figure 1). We examined three
possible PMTCT regimens in Zimbabwe: (1) the 2002–2009
National PMTCT Program, based on sdNVP alone, (2) WHO
2010 guidelines’ Option A, and (3) WHO 2010 guidelines’ Option
B. Infant outcomes were projected at four levels of PMTCT
uptake (36%, 56%, 90%, and 95% of women/infants receiving
medications by the time of infant delivery) [19,23]. Key sensitivity
analyses examined the impacts of duration of breastfeeding,
maternal HIV disease stage, the range of published MTCT risks
for each PMTCT regimen, and a ‘‘full’’ (100%) uptake scenario.
Population
The linked models were used to simulate two populations of
pregnant and breastfeeding women in Zimbabwe, with mean age
of 24 y (standard deviation [SD]: 5 y) [33]. Cohort 1 included
women already HIV-infected at their first ANC visit (regardless of
whether HIV status was known to patients or providers). Cohort 2
was composed of all women becoming pregnant each year in
Zimbabwe, an estimated 392,460 women [34,35], with HIV
prevalence of 16% at first ANC visit and HIV incidence of 1%/
year during late pregnancy and breastfeeding [36]. Cohort 1 was
thus nested within Cohort 2. Cohort 1 was analyzed to project
MTCT rates, and Cohort 2 to project the proportion and number
of infants in an annual birth cohort anticipated to become HIV-
infected by 18 mo of age. All women were assumed to breastfeed
their infants for 12 mo in the base case, based on WHO infant
feeding guidelines [3].
PMTCT Regimens and PMTCT Uptake Scenarios
The antenatal, intrapartum, and postpartum/neonatal compo-
nents of each modeled PMTCT regimen are detailed in Table A
in Text S1. In all modeled regimens, women identified as eligible
for ART (CD4#350/ml or WHO stage 3/4 disease) were referred
for ART. The availability of ART after referral depended on the
modeled PMTCT uptake scenario; the availability of CD4 assays
was varied in sensitivity analyses. Following convention, we refer
to combination antiretroviral therapy regimens as ‘‘ART’’ when
intended for treatment of maternal HIV disease (also effective for
PMTCT) and as ‘‘triple-drug ARV regimens’’ when offered to
non-ART-eligible women for PMTCT.
To create the four uptake scenarios, the ‘‘cascade’’ of PMTCT
services was categorized into three broad domains (Table 1;
Figure 1): ‘‘care and testing,’’ ‘‘drug availability,’’ and ‘‘retention.’’
We then calculated a ‘‘product of participation’’ (POP), defined as
the product of the proportions of women/infants receiving care in
each of these three domains, both at delivery and at the end of the
breastfeeding period [23]. Four primary scenarios of PMTCT
uptake were simulated for each PMTCT regimen (Table 1). The
first two scenarios reflected WHO and Zimbabwean Ministry of
Health and Child Welfare estimates of uptake at each step in the
PMTCT cascade for Zimbabwe in 2008 (total POP at delivery:
36%) and 2009 (total POP at delivery: 56%) [19,23,36,37]. The
‘‘WHO target’’ scenario modeled the current WHO goal that
80% of pregnant women be HIV-tested and 80% of HIV-infected
women receive PMTCT services [20,37]. The ‘‘optimal’’ uptake
scenario simulated 95% uptake of the complete PMTCT cascade
through delivery, likely representing the best practically achievable
Table 1. PMTCT uptake scenarios.
Scenario Care and Testing
a Drug Availability
b Retention
c POP
d
Zimbabwe National
PMTCT Program
2008 [23]
ANC: 94% [23]; HIV testing: 75% [37];
result return: 99% [36]; total: 70%
(=94%675%699%)
86% Before delivery: 60% (mean of
[11,24,43–47])
To delivery: 36% [23]
Postpartum: if ANC, 87% (mean of
[11,43,44,48–50]); if no ANC, 43%
(assumption: 50%)
To 18 mo postpartum:
31%
Zimbabwe National
PMTCT Program
2009 [19]
ANC: 91% [36]; HIV testing: 87% [36];
result return: 99% [36]; total: 78%
(=91%687%699%)
82% Before delivery: 87% [43] To delivery: 56% [19]
Postpartum: if ANC, 87% (mean of
[11,43,44,48–50]); if no ANC, 43%
(assumption: 50%)
To 18 mo postpartum:
49%
WHO target [37] ANC: 100%; HIV testing: 80%; result return:
100%; total: 80% (=100%680%6100%)
100% Before delivery: 100% To delivery: 80%
Postpartum: if ANC, 87% (mean of
[11,43,44,48–50]); if no ANC, 43%
(assumption: 50%)
To 18 mo postpartum:
70%
Optimal (95%) uptake ANC: 100%; HIV testing: 95%; result return:
100%; total: 95% (=100%695%6100%)
100% Before delivery: 100% To delivery: 95%
Postpartum: if ANC, 87% (mean of
[11,43,44,48–50])
To 18 mo postpartum:
83%
aProportion of pregnant women accessing ANC, HIV testing for those in ANC, and receipt of HIV test result for those tested.
bProportion of ANC sites with access to medications for PMTCT. This proportion is back-calculated in order to reach the reported POP for each scenario.
cOf women offered ARVs for PMTCT, the proportion remaining in care during the antenatal period, used as a proxy for acceptance of and adherence to medications.
Retention in care postpartum: Of all postpartum women, the proportion linking to HIV care by the 6-wk postpartum visit. Impacts on MTCT of loss to follow-up after
6 wk postpartum, in the absence of specific data, are incorporated into highest-risk transmission estimates.
dProportion of patients receiving care at all stages of the PMTCT cascade, defined as the product of (drug availability)6(care and testing)6(retention).
doi:10.1371/journal.pmed.1001156.t001
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regimens. A scenario of full, 100% uptake was also examined in
sensitivity analyses (Tables D–G in Text S1), to represent the
maximum potential biologic efficacy of each regimen.
Model Structure
Antenatal and intrapartum outcomes: MTCT model.
The MTCT model is a previously published, decision-analytic
simulation of a cohort of pregnant women from the time of
conception through delivery (TreeAgePro) [28,29]. The model
uses a decision-tree (deterministic) structure, including prob-
abilities of the following: presentation to ANC; offer and
acceptance of HIV testing; receipt of HIV test results; clinical
assessment for ART eligibility; CD4 testing and receipt of results;
offer of, acceptance of, and adherence to ARVs for PMTCT;
maternal mortality during pregnancy; HIV testing in labor for
women with unknown or negative HIV status; live birth; infant
HIV infection by the time of delivery; and linkage to postnatal care
and ART for mothers and infants (Figure A in Text S1).
Postnatal outcomes: CEPAC adult model. The CEPAC
model of adult HIV infection is a computer simulation model of
HIV disease in adults. Technical details of the CEPAC model are
described in Text S1 [30,38]; outcomes of the CEPAC model for
postpartum women have been validated against published data
(Text S1) [32]. For this analysis, the adult CEPAC model was used
only to project maternal mortality risks during the first 2 y after
delivery, in order to inform infant mortality rates and duration of
breastfeeding in the infant model.
Postnatal outcomes: CEPAC infant model. A first-order,
Monte Carlo simulation model of infant HIV infection and
survival was added to the adult CEPAC model (Figure B in Text
S1) [29]. Infants enter this model at birth and are assigned one of
three HIV categories (HIV-unexposed, HIV-exposed but
uninfected, or HIV-infected), as well as one of three maternal
disease categories (HIV-uninfected, HIV-infected and ‘‘ART
eligible,’’ or HIV-infected and ‘‘non-ART-eligible’’). Over the
first 2 y of life, modeled infants face a monthly probability of four
key clinical events: (1) incident maternal HIV infection during
breastfeeding, if mother was previously uninfected, causing infants
to transition from ‘‘unexposed’’ to ‘‘exposed, uninfected’’; (2)
maternal death, with risks derived from the adult CEPAC model
as above, after which infants are no longer at risk for HIV
infection but are at higher risk of death due to orphanhood
[39–42]; (3) infant HIV infection through breastfeeding, if infant
was previously uninfected; and (4) infant death from any cause.
Risks of infant mortality are stratified by infant HIV exposure and
infection status, by receipt of ART if infected, and by maternal
vital status.
The MTCT and CEPAC models were linked to allow a
combined analysis in which each woman–infant pair is
simulated together from the time of first presentation at ANC
through pregnancy and delivery (the MTCT model), and then
each woman and infant are simulated separately through the
first 2 y postpartum (the CEPAC models). Details of the
linkages between the CEPAC and MTCT models have been
published previously [29] and are further described in Figures A
and B in Text S1.
Loss to follow-up. During ANC in the MTCT model,
women may be lost to follow-up between first ANC presentation
and delivery [11,24,43–47], between delivery and 6 wk
postpartum [11,43,44,48–50], and after linkage to postnatal HIV
care [43,44,51–56]. In the absence of data regarding rates of
adherence to the Option A or Option B regimens during
breastfeeding, the impacts of medication interruptions or
discontinuations were assumed to be included in sensitivity
analyses examining ‘‘highest risk’’ postnatal MTCT estimates.
Model Input Parameters
Baseline maternal characteristics reflected cohorts of pregnant
women in Zimbabwe (Table 2). At first ANC visit, mean age was
24 y (SD: 5 y) [57], and the proportion with CD4#350/ml was
36%, based on data from Zimbabwe [58]. In the base case,
MTCT risks were derived as the average (mean or midpoint) of
risks reported in PTMCT studies in Africa (Table 3; Text S1)
[4–10,12–15,58–69]. To avoid underestimating early postpartum
MTCT risks, we included only data from breastfed infants,
necessarily excluding pivotal PMTCT studies among replacement-
fed populations [8,70–72]. In the absence of reported postnatal
transmission risks for infants older than 6 mo of age who continue
to breastfeed with ongoing prophylaxis (Option A or B), we
assumed a constant monthly risk based on data in younger
children, as has been observed for postnatal transmission without
prophylaxis [73]. Infant mortality rates (Table 4) were derived
from Joint United Nations Programme on HIV/AIDS HIV-
deleted mortality estimates (HIV-unexposed infants) [74], the
ZVITAMBO study in Zimbabwe (HIV-exposed, uninfected
infants) [75], and pooled analyses of several African cohorts
(HIV-infected infants) [26,76,77].
Model Validation and Sensitivity Analyses
Validation of model-derived MTCT and mortality risks against
published data, and sensitivity analyses on many clinical and
programmatic parameters, have been reported previously [29].
For this analysis, in addition to the impact of PMTCT uptake
and regimen examined in the base-case analyses, we conducted
univariate sensitivity analyses on three key factors influencing
transmission risk. First, to examine the impact of the range of
published MTCT risks for each regimen, we defined ‘‘highest risk’’
and ‘‘lowest risk’’ scenarios. The ‘‘lowest risk’’ scenarios use the
lowest published MTCT risks for each drug regimen, reflecting the
best reported field effectiveness or trial efficacy, and likely
representing the most adherent study populations; the ‘‘highest
risk’’ scenarios use the highest published MTCT risks for each
drug regimen. Second, because the proportion of women with
CD4#350/ml or WHO stage 3/4 disease at first ANC visit has
been reported to range widely (23%–68% [78,79]), we varied this
proportion in sensitivity analyses from 0% to 100%. Third, we
investigated the contribution of prolonged breastfeeding by
projecting MTCT risk at 4–6 wk of age (primarily reflecting
transmission that occurs in the absence of breastfeeding), as well as
after 18 mo of breastfeeding (the median duration reported in a
cohort from Zimbabwe [58]), with ARV prophylaxis continued
throughout breastfeeding.
We identified the parameters that exerted the greatest impact
on MTCT risks by comparing the range of MTCT risks projected
when each parameter was varied through clinically plausible
ranges; the largest range of projected MTCT risks reflected
parameters with the greatest influence on model results. We then
performed multivariate sensitivity analyses to determine combi-
nations of these factors necessary to reach MTCT risks less than
5%.
To further examine the multiplicative impact of individual
components of the PMTCT cascade, we varied uptake at each
step in the care pathway (access to ANC, HIV testing in ANC,
receipt of HIV test results, medication availability, adherence to
medications, and linkage to postnatal HIV-related care), as well as
the availability of CD4 counts and ART for women with
CD4#350/ml.
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Maternal HIV Status PMTCT Regimen Received
No ARVs sdNVP Antenatal ZDV
a
Extended
Infant NVP Triple-Drug Regimen
Intrauterine/intrapartum period (one-time risks)
ART-eligible at conception 0.273 [60,93] (0.199–0.322)
[64,93,94]
0.176 [58,79] (0.082–
0.264) [4,14,65,95]
0.136 [62] (0.091–
0.157) [7,96]
n/a 0.033 [7] (0.011–0.041) [6,9,13]
Non-ART-eligible at conception 0.175 [60,93] (0.127–0.206)
[64,93,94]
0.073 [58,79] (0.033–
0.109) [4,14,65,95]
0.036 [62] (0.024–
0.041) [13,67,96]
n/a 0.01 [9] (0.004–0.028) [8,9]
Incident infection during
pregnancy
0.30 (assumption) 0.20 (assumption) 0.16 (assumption) n/a 0.033 (assumed=eligible)
Postnatal period (rate/100 person-years, among infants HIV-uninfected at 4–6 wk of age)
ART-eligible 9.13 (EBF) [58,79]; 15.43 (MBF)
[58,79] (5.73–28.36) [61,94]
n/a n/a n/a 4.00 [67] (0–6.42) [7–9,13]
Non-ART-eligible 2.86 (EBF) [58,79]; 4.82 (MBF)
[58] (1.79–8.82) [61,69]
n/a n/a 2.65 [5,10]
(1.44–3.74) [5,10]
2.23 [9,11,12,15] (0–6.42)
[9,10]
Incident infection during
breastfeeding
9.13 (EBF) [58,79]; 15.43 (MBF)
[58,79] (5.73–28.36) [61,94]
n/a n/a n/a 4.00 [67] (0–6.42) [7–9]
(assumed=eligible)
Data given as base-case value [references] (range for sensitivity analysis) [references].
aAntenatal ZDV reflects the antenatal component of the Option A regimen for women who are not eligible for ART. Per WHO 2010 PMTCT guidelines, the intrapartum
sdNVP and 7-d postnatal ZDV/lamivudine ‘‘tail’’ components of the Option A regimen may be omitted if a woman receives.4 wk of antenatal ZDV. The cited
transmission risks reflect a range of antenatal ZDV treatment durations, as well as studies both including and excluding the sdNVP and ZDV/lamivudine components.
The Pediatric AIDS Clinical Trials Group Protocol 076 study [96] was conducted in a replacement-fed population. However, this study demonstrated MTCT risks at the
upper bound of the published range, reducing concern for underestimation of early postpartum MTCT risk, and thus was used in the ‘‘highest risk’’ scenario.
EBF, exclusive breastfeeding (in first 6 mo of life, followed by mixed breastfeeding); MBF, mixed breastfeeding; n/a, not applicable.
doi:10.1371/journal.pmed.1001156.t003
Table 2. Model input parameters: maternal characteristics and uptake of PMTCT services.
Variable Base-Case Value
Range for Sensitivity
Analyses Data Sources
Baseline maternal cohort characteristics
Age 24 (5) 20–30 MOHCW [57]
HIV prevalence 16% MOCHW [36]
HIV incidence 1%/y MOHCW [36]
Mortality during pregnancy 0.7% 0%–2% MOHCW [36]
Among HIV-infected women at first ANC visit
Proportion ART-eligible
a 36% 0%–100% ZVITAMBO trial [58]
CD4 count: total cohort 451 (50) ZVITAMBO trial [58]
CD4 count: ART-eligible 275 (50) ZVITAMBO trial [58]
CD4 count: non-ART-eligible 550 (50) ZVITAMBO trial [58]
CD4 count: incident infection in pregnancy 664 (50) MACS [92]
Uptake of PMTCT services and postnatal care (equal for all coverage scenarios)
Sensitivity of clinical assessment of ART eligibility
a 36% 20%–100% MTCT-Plus cohort [80]
Delivery in health care facility 69% 50%–100% MOHCW [36]
Probability of linking to pediatric HIV diagnosis,
care, and ART
36% 0%–100% WHO/United Nations Children’s Fund
[23]
Duration of breastfeeding (months) 12 0–18 WHO, ZVITAMBO trial [3,58]
Age given as mean (SD) in years; CD4 counts given as mean (SD) in number/microliter. Maternal disease progression: details of the CEPAC model and data inputs
describing maternal HIV disease progression with and without ART are provided in Text S1.
aART eligibility defined as CD4#350/ml or WHO stage 3/4 disease. In scenarios in which CD4 assays were not available, we simulated clinical assessment of ART eligibility.
The sensitivity of clinical assessment of ART eligibility was reported for a CD4 threshold of 200/ml (36%); model sensitivity analyses using subsequent reports based on a
CD4 threshold of 350/ml (sensitivity: 20%) did not substantially change the results [80].
MACS, Multicenter AIDS Cohort Study; MOHCW, Zimbabwe Ministry of Health and Child Welfare.
doi:10.1371/journal.pmed.1001156.t002
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MTCT Risk among Infants Born to Women HIV-Infected
Before Pregnancy (Cohort 1)
The modeled 12-mo MTCT risk in the sdNVP-based 2008
Zimbabwean National PMTCT Program was 20.3% (Table 5,
top). Modeled improvements in PMTCT uptake in the 2009
National PMTCT Program are projected to have reduced this risk
to 18.0%. If sdNVP could be replaced by WHO-recommended
regimens at the current 56% uptake level, MTCT risk would be
projected to fall to 14.4% with Option A, or 13.4% with Option B.
The potential impacts of further improvements in coverage are
highlighted in the ‘‘WHO target’’ and ‘‘optimal uptake’’ scenarios.
If Option A were implemented at the WHO target level of 80%,
MTCT risk would be projected to fall to 10.5%; ‘‘optimal’’ 95%
uptake would reduce this further to 7.7%. With Option B, these
risks are projected at 9.1% (80% uptake) and 6.1% (95% uptake).
Similar impacts of PMTCT regimens and uptake scenarios are
seen for the secondary outcomes of infant infection risk at 4–6 wk
of age, 2-y pediatric survival, and 2-y pediatric HIV-free survival
(Tables E–G in Text S1).
Population-Level Results for All Women Becoming
Pregnant Each Year in Zimbabwe (Cohort 2)
For an annual pregnancy cohort in Zimbabwe, incorporating
HIV-negative women, chronically HIV-infected women, and
women with incident HIV infection (Table 5, bottom), the overall
modeled 12-mo risk of infant HIV infection under the 2008
National PMTCT Program was 3.5%, representing 13,910 HIV-
infected infants. Improvements in uptake are modeled to have
reduced this risk to 3.2% (12,440 infections) by 2009, averting
1,470 infections. Replacement of sdNVP by Option A or B at the
current uptake level would be projected to reduce this risk to
2.4%–2.6% (9,560–10,200 infections), and improved levels of
uptake would reduce this modeled risk further, to 1.3% (4,950
infections, a 60% reduction in infant infections compared to
sdNVP at 56% uptake) with Option B at ‘‘optimal’’ 95% uptake.
Table 4. Model input parameters: infant mortality.
Variable Base-Case Value Range for Sensitivity Analyses Data Source
Probability of live birth 95.7%–98% 95%–99% MOHCW [57]
Relative increase in infant mortality if maternal
death occurs
2-fold increase 2- to 6-fold increase [39–42]
HIV-unexposed children 1-y risk: 5.4% [74]
2-y cumulative risk: 5.9%
HIV-exposed, uninfected children 1-y risk: 7.4% [75]
2-y cumulative risk: 9.2%
HIV-infected children, no ART: intrauterine/
intrapartum infection
1-y risk: 51.0% [26]
2-y cumulative risk: 65.0%
HIV-infected children, no ART: postpartum infection 1-y risk: 24.0% [26]
2-y cumulative risk: 38.0%
HIV-infected children, on ART 1-y risk: 9.5% [77,97]
2-y cumulative risk: 12.0%
MOHCW, Zimbabwe Ministry of Health and Child Welfare.
doi:10.1371/journal.pmed.1001156.t004
Table 5. Results of a model of PMTCT services in Zimbabwe: cumulative 12-mo infant HIV infection risks.
Uptake Scenario Base-Case Model Results for Each PMTCT Regimen
sdNVP WHO 2010 Option A WHO 2010 Option B
Infants of women HIV-infected before pregnancy: MTCT risk (%)
Zimbabwe National PMTCT Program 2008 (36%) 20.3 17.9 17.2
Zimbabwe National PMTCT Program 2009 (56%) 18.0 14.4 13.4
WHO target (80%) 15.4 10.5 9.1
Optimal (95%) 13.4 7.7 6.1
Infants of annual cohort of pregnant women in Zimbabwe: proportion (%) of cohort (number of annual infections; reduction from 2009 program)
Zimbabwe National PMTCT Program 2008 (36%) 3.5 (13,910) 3.2 (12,380) 3.0 (11,950)
Zimbabwe National PMTCT Program 2009 (56%) 3.2 (12,440; reference) 2.6 (10,200; 18%) 2.4 (9,560; 23%)
WHO target (80%) 2.8 (10,790; 13%) 2.0 (7,750; 38%) 1.8 (6,890; 45%)
Optimal (95%) 2.4 (9,590; 23%) 1.5 (5,970; 52%) 1.3 (4,950; 60%)
doi:10.1371/journal.pmed.1001156.t005
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Univariate sensitivity analyses investigating the individual
impacts of PMTCT uptake, lowest/highest risk scenarios,
maternal CD4 count, breastfeeding duration, and PMTCT
regimen among Cohort 1 are shown in Figure 2. When individual
parameters were varied from the base-case scenario (Option A
regimen, 12 mo of breastfeeding, 36% of mothers ART-eligible,
and average of published MTCT risks for each regimen), PMTCT
uptake was the most influential single parameter (Figure 2, widest
bar). Projected transmission, with all other parameters held equal,
ranged from 6.2% (100% uptake), through 14.4% (56% uptake,
indicated by ‘‘base-case projection line’’), to 17.9% (36% uptake).
The second most influential parameter was the range of published
MTCT risks for each regimen (ranges shown in Table 3): with
Option A at 56% uptake, 12-mo MTCT risks ranged from 8.8%
(‘‘lowest risk’’) to 18.5% (‘‘highest risk’’). The individual impacts of
PMTCT uptake and lowest/highest risk scenarios, as well as of
maternal CD4 count and breastfeeding duration, were greater
than the impact of the choice of PMTCT regimen (Figure 2,
narrowest bar). Additional univariate sensitivity analyses suggested
that variations in the availability of HIV testing in labor and
sdNVP for women identified as HIV-infected during labor also did
not change the policy conclusions (Text S1). Overall, these
univariate sensitivity analyses demonstrated that optimizing any
single parameter shown in Figure 2 did not reduce modeled
MTCT risk to less than 5%, underscoring the need for
improvements in multiple parameters simultaneously to approach
the ‘‘virtual elimination’’ of HIV in Zimbabwe.
Multivariate Sensitivity Analyses
Multivariate sensitivity analyses highlighted the combinations of
factors necessary to reduce MTCT among Cohort 1 to the WHO
target of less than 5% (Figure 3, regions shaded in green). For
example, at 80% uptake of Option A (middle panel), only if the
lowest published MTCT risks and avoidance of breastfeeding were
assumed was the ,5% target projected to be achieved. With 80%
uptake of Option B, a projected risk less than 5% still required
assumption of the lowest published MTCT risks, but permitted
breastfeeding durations up to 18 mo. With both the lowest
published transmission risks and ‘‘optimal’’ (95%) uptake, 12-mo
Figure 2. Key parameters determining MTCT risk. Tornado diagram summarizing the results of key one-way sensitivity analyses. Model
parameters are on the vertical axis. For each parameter, the value used in the base-case analysis is listed in parentheses, followed by the range
examined in sensitivity analysis. For example, the ‘‘regimen’’ provided for PMTCT is varied from Option B (lowest MTCT risk with all other parameters
held constant), through Option A (base-case MTCT risk), to sdNVP (highest MTCT risk). The horizontal axis represents projected MTCT risk by the time
of weaning. The solid vertical line represents transmission risk (14.4%) at the base-case set of parameters: 56% uptake, mean published MTCT risks,
36% of mothers with CD4,350/ml, breastfeeding duration of 12 mo, and the WHO ‘‘Option A’’ regimen. The dashed vertical line represents the 5%
MTCT target of ‘‘virtual elimination’’ expressed by international HIV/AIDS agencies including WHO and the Joint United Nations Programme on HIV/
AIDS. ARV prophylaxis in the Option A and Option B regimens is assumed to continue throughout the duration of breastfeeding.
doi:10.1371/journal.pmed.1001156.g002
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B).
Impact of Overall Product of Participation (Cohort 1)
When overall uptake by the time of delivery was held constant
at any given level, the specific step in the cascade at which uptake
was varied did not affect 4–6-wk MTCT risk (Table 6). In contrast,
the proportion of women–infant pairs linking to postnatal care had
a substantial impact on 12-mo MTCT risk, especially with
Options A and B (Table 7).
Impact of Available CD4 Counts and ART for Women with
CD4#350/ml (Cohort 1)
In the base-case analysis, CD4 assays were assumed to be
available only in the Option A and Option B strategies; for
sdNVP, ART eligibility was assessed clinically, with a sensitivity
of 36% for WHO stage 3/4 disease or CD4#350/ml [80].
Furthermore, the proportion of women offered medications was
assumed to be equal among identified ART-eligible women
(offered ART) and all others (offered the sdNVP, Option A, or
Option B regimens). Two modeled scenarios demonstrated the
impact of improvements in CD4 and ART availability. Table 8
(top) depicts a scenario in which no CD4 assays were available,
regardless of regimen. At 56% uptake of sdNVP or Option A,
although 36% of the cohort was truly ART-eligible, only 7% of
HIV-infected women were identified as ART-eligible and
received ART. Table 8 (bottom) shows a scenario in which
CD4 assays were available for all women identified as HIV-
infected in ANC, and all women with CD4 values#350/mlw e r e
offered ART. At 56% uptake of sdNVP or Option A, this
Figure 3. Combinations of parameters needed to achieve MTCT risks,5%, 5%–10%, and .10%. Each horizontal block represents results
for a specific drug regimen: sdNVP (top), Option A (middle), and Option B (bottom). Within each block, four levels of uptake are depicted across the
top horizontal axis: 56% uptake (current estimated uptake in Zimbabwe), 80% uptake (the WHO target), 95% uptake (reported in neighboring
Botswana), and 100% uptake (to reflect maximum biologic efficacy of each regimen). The vertical axis illustrates three durations of breastfeeding (BF)
for each modeled PMTCT regimen: 18 mo (median in Zimbabwe), 12 mo (concordant with 2010 WHO infant feeding guidelines), and no
breastfeeding; ARV prophylaxis in the Option A and Option B regimens is assumed to continue throughout the duration of breastfeeding. The lower
horizontal axis shows three categories of published MTCT risks for each drug regimen, including the lowest published risks, the average of published
risks (the base-case parameters), and the highest published risks. The percentage in each cell reflects the MTCT risk associated with each set of
parameters, and cells are color-coded to reflect broad categories of transmission. Red-colored cells indicate MTCT risks.10%, yellow-colored cells
indicate MTCT risks between 5% and 10%, and green-colored cells indicate MTCT risks,5%.
doi:10.1371/journal.pmed.1001156.g003
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identified as ART-eligible and to receive ART. Although the
proportion of women receiving sdNVP or antenatal ZDV
decreased from 49% to 31% (to maintain a total uptake of
56%), MTCT risks at 4–6 wk were substantially lower when CD4
assays were available. Notably, in the sdNVP strategy at 56%
uptake, adding CD4 assays and ART for eligible women reduced
4–6-wk MTCT from 13.8% to 11.4%, a larger impact than that
of replacing sdNVP with Option A without CD4/ART
availability (4–6-wk MTCT risk of 12.0%). Under the Option
B strategy, the effect of targeting ART to women with low CD4
counts was markedly smaller: at 56% uptake of Option B,
prioritizing ART for women with CD4 values#350/ml would
reduce 4–6-wk MTCT from 9.9% to only 9.6%, by slightly
shifting the distribution of women on three-drug ARVs from non-
ART-eligible to ART-eligible women.
Discussion
We present results from a validated computer simulation model
of MTCT in Zimbabwe, a setting where high HIV prevalence,
prolonged breastfeeding, and limited resources make the WHO
2010 PMTCT guidelines both critical and challenging to
implement. These analyses enumerate the potential benefits of
improved PMTCT services along two dimensions: implementation
of the WHO-recommended Option A or B regimens, and
improved uptake of any given regimen at each step in the
PMTCT cascade (Figure 1). Our results are similar to those from
prior analyses using different modeling methodologies, including
the analyses from which the initial targets were generated;
consistent findings suggest that ‘‘virtual elimination’’ will require
massive scale-up of PMTCT services [22,81]. Although the WHO
target may therefore seem difficult to reach, the WHO’s ‘‘3 by 5’’
campaign (to deliver ART to 3 million HIV-infected patients by
2005) demonstrated the role that such ambitious public health
goals can play in catalyzing efforts to dramatically expand HIV/
AIDS services [82]. In addition, the analyses presented in this
article simultaneously examine PMTCT uptake, breastfeeding
duration, the range of MTCT risks published for each regimen,
and both Options A and B from the 2010 WHO PMTCT
guidelines, to identify combinations of factors that will facilitate
achieving MTCT risks of less than 5% and the ‘‘virtual
elimination’’ of pediatric HIV.
Most importantly, we find that improvements in PMTCT
uptake are critical to approaching the goal of virtual elimination of
MTCT. For example, a marked increase in PMTCT uptake
occurred in Zimbabwe between 2008 (36%) and 2009 (56%),
despite a period of economic hyperinflation [83]; as a result,
projected MTCT risk was reduced from 20.3% to 18.0%, and an
estimated 1,470 additional new infections were averted in a single
year. Furthermore, once sdNVP is replaced by either WHO-
recommended regimen, the level of PMTCT uptake exerts a far
greater impact on MTCT rates than does the specific choice
between Option A and Option B. Building from the 2009 National
PMTCT Program in Zimbabwe, replacing sdNVP with Option A
at 56% uptake (MTCT risk, 14.4%) would be more effective than
expanding sdNVP uptake to 80% (MTCT risk, 15.4%). However,
once the program reaches 56% uptake of Option A, improving
uptake of Option A to 80% (MTCT risk, 10.5%) is projected to
result in better outcomes than would replacing Option A with
Option B at current uptake (MTCT risk, 13.4%). Notably, even
with 95%–100% uptake, there are very few scenarios in which
MTCT risk is estimated to fall below the 5% ‘‘virtual elimination’’
target threshold set by the WHO (Figure 3). With 12 mo of
Table 7. Impact of linkage to postnatal care by 6 wk postpartum, following 56% uptake at delivery.
Regimen 12-mo MTCT Risk (Percent) for Given Linkage to Postnatal Care
0% Linkage 25% Linkage 50% Linkage 75% Linkage
87% Linkage (Base
Case) 100% Linkage
sdNVP 19.8 19.2 18.7 18.2 18.0 17.7
Option A 17.1 16.3 15.5 15.4 14.4 14.0
Option B 16.2 15.4 14.6 14.0 13.4 13.0
To isolate the impact of linkage on postnatal care, results are shown for the base-case scenario of antenatal PMTCT uptake (56% uptake at the time of delivery).
doi:10.1371/journal.pmed.1001156.t007
Table 6. Impact of uptake at key antenatal steps in the PMTCT cascade on MTCT at 4–6 wk of age.
Proportion of Women Accessing Each Step in Cascade MTCT at 4–6 wk
Access ANC HIV Test HIV Test Result Drug Availability Adherence
Total Uptake by
Delivery
91 87 99 82 87 56 13.8
56 100 100 100 100 56 13.8
100 56 100 100 100 56 13.8
100 100 56 100 100 56 13.8
100 100 100 56 100 56 13.8
100 100 100 100 56 56 13.8
Results are shown with 56% uptake, sdNVP strategy. All data given as percents.
doi:10.1371/journal.pmed.1001156.t006
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regimen, nearly 100% uptake of Option B would be required to
reach MTCT risks of less than 5%.
The results of this analysis depend critically on the modeled
effectiveness of each ARV regimen, leading to two key conclusions.
First, Option B may not be superior to Option A in preventing
MTCT. The ranges of published MTCT risks for Options A and B
arewideandoverlapping(Table3),and norandomizedcomparison
of Option A with Option B has yet been reported. While data from
available trials are limited by differences in populations and
interventions [4–15,67,84], they suggest that Options A and B
might have similar efficacy among women with CD4.350/ml,
supporting WHO’s equally strong recommendation of both
regimens [21]. Results of a multi-national clinical trial comparing
these regimens in women with CD4.350/ml will critically inform
policy decisions around Options A and B [85].
Second, the lowest published MTCT risks for each regimen
likely reflect an additional contribution of medication adherence,
beyond that explicitly included in our MTCT model. For
example, the lowest reported MTCT risks with maternal triple-
drug ARV regimens in breastfeeding suggest 0% transmission by
6 mo of age, even among women with CD4,200/ml [9], which is
lower than other reported risks of 0.5%–2.9% [6,7,10–13,15].
Zero transmission was observed in a trial in which 92%–99% of
women achieved viral suppression (HIV RNA,400 copies/ml) at
delivery and 6 mo postpartum, suggesting that sustained adher-
ence might have been greater in this trial than in trials reporting
higher MTCT rates without such suppression data [9]. Among
mother–infant pairs attempting to complete the Option A or
Option B regimens beyond 6 mo of breastfeeding, adherence has
not yet been reported. Based on high reported loss to follow-up
rates among HIV-infected adults on ART, particularly postpartum
women, as well as anecdotal evidence of the challenges of
administering daily medications to otherwise healthy infants, it
might be anticipated that the adherence that is observed when
Options A and B are implemented in treatment programs will be
lower than the trial-based adherence rates that are reflected in our
base-case and ‘‘lowest risk’’ scenarios [43,86].
In addition to the range of published MTCT risks for each
regimen, reduced duration of breastfeeding is a key parameter
Table 8. Impact of availability of CD4 assays and ART for women with CD4#350/ml.
Scenario Uptake of Specific Regimens (Percent of Entire Cohort) Outcomes
ART (Identified as ART-
Eligible) sdNVP ZDV
Total Uptake, Any
Regimen MTCT at 4–6 wk MTCT at 12 mo
a
Clinical assessment of ART eligibility (CD4 assay not available); equal availability of ART for women identified as ART-eligible and of ARVs for all
others
56% uptake
sdNVP 7 49 0 56 13.8 18.0
Option A 7 0 49 56 12.0
b 15.6
b
Option B 20 0 0 56 9.9 13.4
80% uptake
sdNVP 10 70 0 80 11.1 15.0
Option A 10 0 70 80 8.6 11.6
Option B 29 0 0 80 5.5 8.5
95% uptake
sdNVP 12 83 0 95 9.4 13.3
Option A 12 0 83 95 6.4 9.6
Option B 34 0 0 95 2.8 5.9
CD4 assay available for all women identified as HIV-infected, and ART available for all women with observed CD4#350/ml
56% uptake
sdNVP 25 31 0 56 11.4
b 15.8
b
Option A 25 0 31 56 10.3 14.0
Option B 25 0 0 56 9.6 13.1
80% uptake
sdNVP 36 44 0 80 7.6 11.7
Option A 36 0 44 80 6.1 9.3
Option B 36 0 0 80 5.0 8.1
95% uptake
sdNVP 36 59 0 95 6.2 10.3
Option A 36 0 59 95 4.1 7.4
Option B 36 0 0 95 2.6 5.8
aResults highlight that providing CD4 assays for all women identified as HIV-infected, and ART for all women with CD4#350/ml would lead to projected MTCT risks
under the 2009 sdNVP-based program (56% uptake, sdNVP strategy: 11.4% at birth and 15.8% at 12 mo) comparable to if Option A were implemented at 56% uptake
without increased CD4 and ART availability (56% uptake, Option A strategy: 12.0% at birth and 15.6% at 12 mo).
doi:10.1371/journal.pmed.1001156.t008
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where replacement feeding is the norm, MTCT risks have been
reduced to 0%–2% [1,2]. However, in Zimbabwe, as in many
other resource-limited settings, infant formula milk may not be
available, affordable, socially acceptable, or safe (due to lack of
clean water or facilities for clean formula preparation) [3].
Replacement feeding, while reducing HIV transmission risk,
therefore confers high risks of diarrheal disease, malnutrition, and
mortality [3,8]. Interventions to safely reduce breastfeeding
duration in such settings, such as improved societal infrastructure
for safe water systems, would likely confer tremendous health
benefits, extending far beyond the infants of HIV-infected
women, but will be costly and challenging to implement [87].
In the interim, our results suggest that promotion of high levels of
access to postnatal care and adherence to ARV prophylaxis
during breastfeeding will be critical to reduce the risk of MTCT
to less than 5%.
Although PMTCT uptake in low- and middle-income countries
has risen from 10% in 2004 to 53% in 2009 [19,37], greater access
to care and medications for HIV-infected pregnant women is still
needed. The PMTCT ‘‘cascade’’ of care comprises multiple steps
at which pregnant and breastfeeding women and their infants can
be lost from care, and overall uptake is reduced multiplicatively at
each step [22,24,25,88]. For example, considering eight steps
(access to ANC, HIV testing, receipt of test result, CD4 testing,
receipt of CD4 result, adherence/retention before delivery,
presentation to postnatal care, and adherence to breastfeeding
prophylaxis regimens), each with the 92% average uptake
observed in the PEARL multi-country study [24], the proportion
of women completing care may be as low as 0.92
6=61% by
delivery, or 0.92
8=51% by weaning. Notably, we find that the
specific step in the antenatal PMTCT cascade at which
improvements are made does not impact the risk of MTCT, if
uptake is improved equally among ART-eligible and non-ART-
eligible women. However, large reductions in the risk of MTCT
are projected to occur if PMTCT uptake is increased by
improving the proportion of ART-eligible women who receive
ART (for example, through greater availability of CD4 testing and
timely CD4 result return, or through selection of the Option B
strategy). In addition, interventions to improve linkage to postnatal
maternal HIV-related care (and ART for ART-eligible breastfeed-
ing mothers) may substantially reduce postnatal HIV transmission.
A focused operational research agenda is critical to identify,
implement, and evaluate interventions that improve uptake and
retention at each step in the PMTCT cascade, with a particular
focus on availability of CD4 assays and ART for women with low
CD4 counts [89].
There are three main limitations to this analysis. First, computer
models simplify complex biologic and operational processes.
Second, data from multiple sources were necessarily combined.
However, sensitivity analyses were conducted to examine the
effects of variation in key simplifying assumptions, including CD4
assay availability and the availability of HIV testing and sdNVP
during labor, as well as wide ranges for each model input
parameter. We found that these assumptions and data inputs had
no substantive impact on policy conclusions, except where
highlighted in the Results and Discussion. Finally, we report only
short-term pediatric outcomes, and exclude potential impacts on
maternal or community health resulting from expansion of
PMTCT programs. In addition to a reduction in infant HIV
infections, many other benefits may result from the planned
transition from sdNVP to Option A or B, including the avoidance
of exposure to sdNVP and the associated risk of drug-resistant
virus for both mothers and infants [90,91], as well as long-term
maternal and pediatric health benefits associated with the
monitoring and treatment infrastructure required for implemen-
tation of more complex PMTCT regimens. The potential health
benefits and costs of these ‘‘indirect effects’’ will comprise
important areas of future research.
Conclusions
In Zimbabwe, the planned implementation of the 2010 WHO
PMTCT guidelines with Option A is projected to substantially
reduce infant HIV infection risk compared to the 2009 national
program. In order to approach the goal of ‘‘virtual elimination’’ of
pediatric HIV (MTCT risk less than 5%), a national program
based on either Option A or Option B will also need to include
strategies to improve PMTCT uptake to nearly 100% throughout
pregnancy and breastfeeding, to safely reduce the duration of
breastfeeding, and to support medication adherence (thereby
maximizing the effectiveness of each ARV regimen) during both
pregnancy and breastfeeding.
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Background A woman who is infected with HIV can pass the
virus to her baby during pregnancy, labor and delivery, or
breastfeeding—mother-to-child HIV transmission (MTCT).
Without treatment, up to 30% of babies born to HIV-infected
women will become infected with HIV during pregnancy or at
delivery, and a further 5%–20% will become infected through
breastfeeding. In2009, around400,000children under 15years
of age became infected with HIV, mainly through MTCT—90%
of these MTCT infections occurred in Africa.
In addition to preventing HIV infection among prospective
parents and avoiding unwanted pregnancies among HIV-
positive women, effective prevention of MTCT (PMTCT)
requires preventing the transmission of HIV from infected
mothers to their infants during pregnancy, labor, delivery,
and breastfeeding.
In 2010, the World Health Organization (WHO) published
new guidelines for PMTCT based on combination antiretro-
viral therapy for women with advanced HIV disease, and two
options for countries to select for women with less advanced
disease. Option A includes zidovudine (ZDV) during preg-
nancy and single-dose nevirapine (sdNVP) at delivery,
followed by daily nevirapine syrup for infants throughout
the duration of breastfeeding; Option B includes maternal
triple-drug ARV regimens throughout pregnancy and
breastfeeding. However, WHO estimates that only 53% of
pregnant women worldwide received any antiretroviral
medicines for PMTCT in 2009.
Why Was This Study Done? As in many sub-Saharan
African countries where prolonged breastfeeding is
common, and necessary to improve child health,
Zimbabwe is implementing the 2010 WHO guidelines with
Option A. However, because of the challenges of enrolling
and retaining women in PMTCT programs, the effectiveness
of this strategy is unknown. Therefore in this study, the
researchers used a model to calculate the level of PMTCT
uptake in Zimbabwe, the PMTCT drug regimens, and the
duration of breastfeeding that would be necessary to reach
the WHO goal of an MTCT risk below 5%.
What Did the Researchers Do and Find? The researchers
used a validated computer simulation model developed
for analyzing the cost-effectiveness of preventing AIDS
complications to measure risk of infant HIV transmission at
the time of weaning, the HIV infection risk at 4–6 weeks of
age, infant survival at two years of age, and 2-year HIV-free
survival. The researchers used four scenarios of PMTCT
uptake and linked the models to two populations of
pregnant and breastfeeding women (mean age, 24 years)
in Zimbabwe, and then analyzed the combinations of the
factors necessary to reach MTCT risks less than 5%.
At baseline, the researchers found that the 2008 National
PMTCT Program in Zimbabwe led to a projected 12-month
MTCT risk of 20.3%. The projected risk in 2009 was 18.0%
because of improved uptake. The estimated MTCT risk with
Option A at 56% uptake (2009 levels) was 14.4% and with
Option B was 13.4%. However, even with greatly increased
uptake, such as 95% levels, the researchers found that
projected transmission risks would exceed the WHO goal of
less than 5% MTCT, and that the MTCT risk would fall below
5% at the 95% uptake level only if the lowest transmission
risks were used for each drug regimen, or if breastfeeding
duration were shortened.
What Do These Findings Mean? These findings show
that the planned implementation of the 2010 WHO PMTCT
guidelines with Option A in Zimbabwe could substantially
reduce infant HIV infection risk compared to the 2009
national program with sdNVP. Furthermore, in order to reach
a MTCT risk of less than 5%, a national program based on
either Option A or Option B will also need to include
strategies to improve access to PMTCT services (to almost
100% uptake), retain women in care, and support medication
adherence throughout pregnancy and breastfeeding. These
findings from a resource-limited country with high HIV
prevalence and prolonged breastfeeding may be useful for
other countries in sub-Saharan Africa.
Additional Information Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001156.
N Avert gives some more information on MTCT and PMTCT.
N The United Nations Children’s Fund has factsheets on
national PMTCT responses in the most affected countries.
N WHO’s strategic vision for PMTCT for 2010–2015 is also
available.
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